Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7

We investigated the efficacy of a small molecule ASR-600, an analog of Urolithin A (Uro A), on blocking androgen receptor (AR) and its splice variant AR-variant 7 (AR-V7) signaling in castration-resistant prostate cancer (CRPC). ASR-600 effectively suppressed the growth of AR+ CRPC cells by inhibiti...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Balaji Chandrasekaran, Ashish Tyagi, Uttara Saran, Venkatesh Kolluru, Becca V. Baby, Venkat R. Chirasani, Nikolay V. Dokholyan, Jyh M. Lin, Amandeep Singh, Arun K. Sharma, Murali K. Ankem, Chendil Damodaran
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Subjects:	CRPC Androgen Receptor AR-Splice Variants N-terminal domain small molecule growth inhibition
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1137783/full